Home / Health / Weight Loss Drug Cuts Heavy Drinking Days
Weight Loss Drug Cuts Heavy Drinking Days
1 May
Summary
- Semaglutide reduced heavy drinking days by 41% in a recent study.
- The drug mimics a gut hormone, signaling fullness to the brain.
- It may be more effective than current alcohol use disorder medications.
A recent study published in The Lancet indicates that semaglutide, a medication commonly prescribed for weight loss, could also be effective in reducing alcohol consumption among adults with both obesity and alcohol use disorder. In a six-month trial involving 108 participants, those who received weekly semaglutide injections alongside therapy saw their heavy drinking days decrease by approximately 41%. This compared to a 26% reduction observed in the placebo group, with alcohol intake levels verified by blood tests.
Semaglutide belongs to the GLP-1 receptor agonist class, mimicking a hormone that signals satiety. Beyond its weight-management benefits, this drug may offer a novel treatment for alcohol use disorder, a condition causing about 5% of global deaths. Experts note that semaglutide's potential efficacy might exceed that of current FDA-approved medications for alcohol use disorder, which include naltrexone, acamprosate, and disulfiram.
Participants also reported reduced alcohol cravings and overall consumption, alongside weight loss and improved blood sugar control. While the study was small and predominantly featured white participants with obesity, the findings are encouraging. Researchers speculate that semaglutide may influence the brain's reward pathways. Side effects were generally mild gastrointestinal issues, similar to those seen in other GLP-1 uses. The study highlights the importance of combining medication with therapy for optimal results.
